Xenon Pharmaceuticals (NASDAQ:XENE) saw its stock surge 5.54% in after-hours trading on Monday, following the release of its second-quarter 2025 financial results that significantly exceeded analyst expectations.

The biopharmaceutical company reported quarterly earnings of $1.07 per share, dramatically outperforming the analyst consensus estimate of a $0.99 loss. This represents a remarkable 207.65% beat and a 242.67% improvement from the $0.75 loss per share reported in the same period last year. The strong earnings performance comes despite a net loss of $84.71 million for the quarter, which was slightly higher than the expected $79.3 million loss.

While Xenon did not report any revenue for the quarter, investors appeared to focus on the positive aspects of the report. The company's cash position remains strong, with cash and cash equivalents and marketable securities totaling $624.8 million as of June 30, 2025. This robust financial position, coupled with the better-than-expected earnings per share, likely contributed to the stock's after-hours rally. As Xenon continues to advance its pipeline of neurology-focused therapies, the market seems optimistic about the company's future prospects and financial management.